Pyrazolam
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral, Sublingual, rectal |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 17 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C16H12BrN5 |
| Molar mass | 354.211 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pyrazolam (SH-I-04)[2] is a benzodiazepine derivative originally developed by a team led by Leo Sternbach at Hoffman-La Roche in the 1970s.[3] It has since been "rediscovered" and sold as a designer drug since 2012.[4][5][6]
Pyrazolam has structural similarities to alprazolam[7] and bromazolam. Unlike other benzodiazepines, pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine.[4]
Legal status
[edit | edit source]United Kingdom
[edit | edit source]In the UK, pyrazolam has been classified as a Class C drug by section 5 of the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.[8]
United States
[edit | edit source]Unscheduled at the federal level.
Alabama made Pyrazolam a schedule I substance on March 18th, 2014.[9]
Synthesis
[edit | edit source]
The condensation of bromazepam (1) with methylamine and titanium tetrachloride gives the amidine (2). Treatment with nitrous acid gives the nitrosylation product (3). Further reaction with hydrazine gives (4), which is treated with triethyl orthoacetate to complete the synthesis of pyrazolam.[10]
See also
[edit | edit source]References
[edit | edit source]- ^ (customs (prohibited imports) regulations 1956 - schedule 4, 1956)
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ US 3954728, Sternbach LH, Walser A, "Preparation of triazolo benzodiazepines and novel compounds", issued Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value)., assigned to Hoffmann La Roche Inc.
- ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ Leo Henryk Sternbach & Armin Walser, U.S. patent 3,954,728 (1976 to Hoffmann La Roche Inc).